T he main objective of this study was to develop paclitaxel loaded poly (caprolactone) injectable microspheres prepared by solvent evaporation method. Mircoparticles were characterized in terms of particle size and size distribution, surface morphology, drug physical state, and crystalline nature by using master size analyzer, scanning electron microscope, differential scanning calorimetry, and X-ray diffraction. Paclitaxel loading over different concentrations was analyzed by high-performance liquid chromatography. In vitro drug release studies were performed in phosphate buffer saline. Best formulation was selected for in vitro cytotoxic studies by using MCF-7 breast cancer cell lines.

T he aim of the present research work was to develop the biodegradable polymeric implant for the delivery of antineoplastic drug, paclitaxel (PTX) using poly (sebacic-co-recinoleic acid) 70:30 w/w. PTX loaded implants were prepared by indigenously developed melt molding technique. Implants were characterized in terms of physico-chemical evaluations, drug content, drug stability and intactness, thermal analysis, drug physical state and crystallinity, surface morphology, hydrolytic degradation, drug release and its kinetics. Prepared implants were yellow and cylindrical in shape with smooth surfaces. Drug in the implants was found to be stable, intact and uniformly dispersed as amorphous state within the polymer matrix. In vitro release, kinetic studies showed zero order and Korsmeyer-Peppas model release being exhibited. Drug release from the polymeric implants was occurred could be as results of diffusion.

I n the present study cylindrical poly(epsilon-caprolactone) (PCL)-based biodegradable polymeric tamoxifen citrate-loaded subdermal implants were prepared by laboratory-based modified melt extrusion technique. The prepared implants were evaluated for their physicochemical parameters. Drug content in implants by high-performance liquid chromatographic (HPLC) method, differential scanning calorimetry (DSC), X-ray diffraction (XRD) and scanning electron microscope (SEM) studies of tamoxifen citrate-loaded implants. Determination of in vitro hydrolytic degradation of polymeric and tamoxifen citrate-loaded implants and in vitro drug release was carried out by using indigenously developed dissolution apparatus. DSC and XRD studies proved that the drug is entrapped in the implant. The highest rate of hydrolytic degradation (weight loss) was observed in blank implants when compared to tamoxifen citrate-loaded implants. The studies proved that the developed method have potential in terms of industrial feasibility.

T he aim of this study was to prepare tamoxifen citrate (TC)-loaded cylindrical and strip-shaped polymeric subdermal implants. The implant was based on poly(ε-caprolactone), a low-melting, biodegradable and biocompatible polymer. Polyethylene glycol (PEG 4000) was used to enhance solubility and release of the drug in the phosphate buffer saline pH 7.4. Implants were prepared by a standardized melt manufacturing method. The prepared implants were evaluated for their physicochemical parameters and drug content in implants by UV spectrophotometric method. PCL-based implants were characterized by Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry, X-ray diffraction studies (XRD) and scanning electron microscopy (SEM). DSC studies showed that the TC in the implants was in the amorphous state. In vitro drug release studies were performed in methanol:phosphate-buffered saline (pH 7.4) at 37±2°C by using horizontal water bath shaker. Stability study was carried out for 90 days, there was no significant change in drug content and other parameters of the PCL-based formulations.

T he main objective of the present study was to prepare paclitaxel (PTX)-loaded poly(sebacic acid-co-ricinoleic ester anhydride) (poly (SA-RA) 70:30 w/w)-based nanoparticles (NPs). PTX-Poly (SA-RA) NPs were prepared by solvent displacement technique. The prepared formulations were characterized in terms of particle size and distribution, surface morphology using Malvern laser analyzer, scanning electron microscope (SEM). Drug physical and chemical state were determined by Fourier transform infrared spectroscopy (FTIR), X-ray diffractometry (XRD) and differential scanning calorimetry. The particles obtained were spherical in shape with a smooth surface and mean particle size in the range of 443-436 nm. The entrapped PTX within the polymer matrix was in the form of amorphous state.